Unique Molecular Features for Vulvar, Vaginal Melanomas

Share this content:
Unique Molecular Features for Vulvar, Vaginal Melanomas
Unique Molecular Features for Vulvar, Vaginal Melanomas

TUESDAY, Jan. 17, 2017 (HealthDay News) -- Vulvar and vaginal melanomas (VVMs) have unique molecular features as compared to nongynecologic melanoma (NGM), according to a study published online Dec. 27 in Cancer.

Jane Y. Hou, M.D., from the Columbia University College of Physicians and Surgeons in New York City, and colleagues compared molecular profiles between VVM and NGM subtypes in order to identify novel, targetable biomarkers. A total of 2,304 malignant melanoma samples were reviewed.

Fifty-one VVMs were compared with 2,253 malignant NGMs (2,127 cutaneous, 105 mucosal, and 21 acral melanomas). The researchers found that B-Raf proto-oncogene serine/threonine kinase (BRAF) was the most frequently mutated gene in VVMs (26 percent), compared with 8.3 percent of mucosal NGMs. Fewer VVMs than NGMs had a variant within the valine codon 600 domain in BRAF-mutated tumors (50 versus 82.1 percent). VVMs had the highest KIT mutation rate (22 percent), compared with 3 and 8.8 percent in cutaneous and mucosal melanoma subtypes, respectively. VVMs rarely had NRAS mutations, compared with cutaneous and acral melanoma subtypes (25.9 and 40.6 percent, respectively). VVMs frequently expressed PD-L1 and PD-1 (56 and 75 percent, respectively), while they rarely had PI3KCA pathway mutation and expression of estrogen receptor/progesterone receptor. Wild-type KIT VVMs were more likely to express molecular markers suggestive of platinum resistance (ERCC1), alkylating sensitivity (MGMT), and anthracycline sensitivity (TOP2A), compared with VVMs that had KIT mutations.

"The unique molecular features of VVM render this disease a distinct subtype of melanoma," the authors write.

One author disclosed being an employee of Caris Life Sciences.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

ACOG: Shared Decision-Making Key to Breast Cancer Screening

ACOG: Shared Decision-Making Key to Breast Cancer Screening

Critically important for patient's value, preferences be factored into process, ACOG leader says

Three Lifestyle Interventions May Slow Cognitive Decline

Three Lifestyle Interventions May Slow Cognitive Decline

Cognitive training, management of hypertension, increased physical activity all help delay decline

CDC: Zika Can Be Found in Placental, Fetal Tissue at Birth

CDC: Zika Can Be Found in Placental, Fetal ...

Of 546 live births with possible maternal Zika virus, 11 percent proved positive

is free, fast, and customized just for you!

Already a member?

Sign In Now »